Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Minimal residual disease (MRD) monitoring is crucial for leukemia and lymphoma treatment protocols.
• Current PCR-based methods using consensus primers for immunoglobulin gene analysis lack sensitivity for MRD monitoring.
• Specific primer assays are sensitive but impractical for routine clinical use due to cost and time.

Purpose of the Study:

• To develop a simple, cost-effective, and sensitive assay for MRD detection in B-cell malignancies.
• To establish a method suitable for routine clinical laboratory use.

Main Methods:

• Development of a novel assay utilizing ligase chain reaction (LCR) to detect clonality.
• Application of LCR for identifying minimal residual disease in B-cell malignancies.

Main Results:

• The LCR assay demonstrates a high sensitivity of 1 cancer cell per 500,000 cells.
• The assay successfully detects all subclones identified in the pre-therapy diagnostic sample.
• The developed method is cost-effective and practical for clinical laboratories.

Conclusions:

• Ligase chain reaction (LCR) provides a sensitive and efficient method for minimal residual disease (MRD) monitoring in B-cell malignancies.
• This assay overcomes the limitations of traditional PCR methods, offering improved clinical applicability.
• The LCR assay supports comprehensive MRD assessment, including the detection of all pre-existing subclones.